Cohance Lifesciences Ltd (NSE: COHANCE) and Onesource Specialty Pharma Limited (NSE: ONESOURCE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Cohance Lifesciences has a market capitalisation of ₹17,104 Cr and Onesource Specialty Pharma ₹17,868 Cr, as of 9 Nov 2026. Return on equity is 5.11% for Cohance Lifesciences and -1.26% for Onesource Specialty Pharma. Over one year, Cohance Lifesciences's share price is down 40.3% and Onesource Specialty Pharma's is down 14.1%.
| Metric | Cohance Lifesciences | Onesource Specialty Pharma |
|---|---|---|
| NSE Symbol | COHANCE | ONESOURCE |
| BSE Code | 543064 | 544292 |
| Share Price | ₹443.50 | ₹1,613.50 |
| Market Cap | ₹17,104 Cr | ₹17,868 Cr |
| P/E Ratio | 95.5 | Not meaningful (loss) |
| Return on Equity | 5.11% | -1.26% |
| Return on Assets | 2.69% | -0.03% |
| Dividend Yield | 0.00% | — |
| Beta (1Y) | 0.37 | 0.25 |
| 1-Year Price Change | -40.3% | -14.1% |
| 3-Month Price Change | -0.8% | +2.4% |
| 52-Week Range | ₹266.70 – ₹715.00 | ₹1,057.00 – ₹1,917.80 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹477 Cr | ₹516 Cr |
| Quarterly Net Profit | ₹2 Cr | ₹57 Cr |
| Net Margin | 0.5% | 11.1% |
| EPS (Basic, Quarter) | ₹0.40 | — |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and …
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoin…
Onesource Specialty Pharma has a market capitalisation of ₹17,868 Cr, against ₹17,104 Cr for Cohance Lifesciences as of 9 Nov 2026, so the two are about the same size by market cap.
Cohance Lifesciences has a return on equity of 5.11% and Onesource Specialty Pharma -1.26%.
Cohance Lifesciences's share price is down 40.3% over one year and Onesource Specialty Pharma's is down 14.1%.
Cohance Lifesciences reported revenue of ₹477 Cr and net profit of ₹2 Cr for Q2 FY27. Onesource Specialty Pharma reported revenue of ₹516 Cr and net profit of ₹57 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.